Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03857321 · ClinicalTrials.gov registry record · Phase 2
Study of Nasal Insulin to Fight Forgetfulness - Device Study
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03857321 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 20 participants.
The verdict
NCT03857321, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The SNIFF Device study will involve using a device to administer insulin through each participant's nose or intra-nasally. Insulin is a hormone that is produced in the body. It works by lowering levels of glucose (sugar) in the blood. This study is measuring how much insulin the device delivers. In addition, this study will look at the effects of insulin or placebo administered intra-nasally using a nebulizer-like device on memory, blood, and cerebral spinal fluid.
Interventions
- OTHER Placebo
- DRUG Insulin
- DEVICE intranasal nebulizer-like device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-04-12 |
| Est. Completion | 2019-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03857321
The ClinicalTrials.gov registry entry for NCT03857321 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03857321 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03857321 about?
NCT03857321 is a clinical study titled "Study of Nasal Insulin to Fight Forgetfulness - Device Study". The SNIFF Device study will involve using a device to administer insulin through each participant's nose or intra-nasally. Insulin is a hormone that is produced in the body. It works by lowering levels of glucose (sugar) in the blood. This study is measuring how much insulin the device delivers. In ...
What is the current status of trial NCT03857321?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2019-04-12. Estimated completion is 2019-09-30.
What interventions are being tested in trial NCT03857321?
The interventions under investigation include: Placebo (OTHER), Insulin (DRUG), intranasal nebulizer-like device (DEVICE).
Who is sponsoring clinical trial NCT03857321?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.